Indivior Pharmaceuticals
INDV34.7900.06% ( +0.020 )
Indivior Pharmaceuticals (INDV)
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for...
- Open
- 34.920
- High
- 35.150
- Low
- 34.560
- Prev. Close
- 34.770
- Volume
- 3.34M
- Turnover
- 116.42M
- Avg Price
- 34.810
- Bid/Ask Ratio
- --
- Amplitude
- 1.70%
- 52wk High
- 42.810
- Volume Ratio
- 2.12
- Turnover Ratio
- 3.06%
- 52wk Low
- 23.990
- Float Mkt Cap
- 3.81B
- Market CapUSD
- 4.11B
- P/ETTM
- 11.53
- P/EDynamic
- 9.73
- P/EStatic
- --
- EPSTTM
- 3.02
- EPSDynamic
- 3.58
- EPSStatic
- --
- BVPS
- -1.76
- P/B
- --
- Circulating Supply
- 109.46M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 118.01M
- Min lot size
- 1
- Currency
- USD
Indivior Pharmaceuticals Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$49.0040.85%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report ·
Selective Institutional Bets Emerge in Medical and Tech Niches
- PUBT ·
Indivior Shareholders Approve Merger With Supernus
- PUBT ·
Supernus Pharmaceuticals Holds Special Stockholder Meeting
- TradingView ·
Indivior to rename as Supernus after merger; supplemental proxy discloses Cantor valuation ranges
- PUBT ·
Indivior Pharmaceuticals announces special shareholder meeting on merger with Supernus
- prnewswire ·
Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders?
